Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05372523 · ClinicalTrials.gov registry record

Senseye's OBCI Diagnostic Tool for PTSD

A clinical trial, sponsored by Senseye.

Terminated
Registry status
61
Enrollment target

NCT05372523 is a clinical trial that was terminated before completion, run by Senseye. The registered enrollment target is 61 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05372523 was terminated before completion, sponsored by Senseye.

TERMINATED
Registry status
61 participants
Enrollment target

Study Summary

This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study with a follow-up time point of 9 weeks post-initial intervention.

Interventions

  • DIAGNOSTIC_TEST CAPS-5 Assessment
  • DIAGNOSTIC_TEST Senseye OBCI

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2022-04-25
Est. Completion 2023-01-11

Sponsor

Senseye

3 total trials

What the Registry Record Tells You About NCT05372523

The ClinicalTrials.gov registry entry for NCT05372523 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senseye, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which CAPS-5 Assessment is the first listed.

NCT05372523 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05372523 about?

NCT05372523 is a clinical study titled "Senseye's OBCI Diagnostic Tool for PTSD". This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study wi...

What is the current status of trial NCT05372523?

This trial is currently terminated. The enrollment target is 61 participants. The study started on 2022-04-25. Estimated completion is 2023-01-11.

What interventions are being tested in trial NCT05372523?

The interventions under investigation include: CAPS-5 Assessment (DIAGNOSTIC_TEST), Senseye OBCI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05372523?

This trial is sponsored by Senseye, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.